|Circulatory syndrome: an evolution of the metabolic syndrome concept!|
|Jump to Full Text|
|PMID: 22845817 Owner: NLM Status: In-Data-Review|
|The metabolic syndrome has been a useful, though controversial construct in clinical practice as well as a valuable model in order to understand the interactions of diverse cardiovascular risk factors. However the increasing importance of the circulatory system in particular the endothelium, in both connecting and controlling organ function has underlined the limitations of the metabolic syndrome definition. The proposed "Circulatory Syndrome" is an attempt to refine the metabolic syndrome concept by the addition of recently documented markers of cardiovascular disease including renal impairment, microalbuminuria, arterial stiffness, ventricular dysfunction and anaemia to more classic factors including hypertension, dyslipidemia and abnormal glucose metabolism; all of which easily measured in clinical practice. These markers interact with each other as well as with other factors such as aging, obesity, physical inactivity, diet and smoking. The final common pathways of inflammation, oxidative stress and hypercoagulability thereby lead to endothelial damage and eventually cardiovascular disease. Nevertheless, the Circulatory (MARC) Syndrome, like its predecessor the metabolic syndrome, is only a small step toward an understanding of these complex and as yet poorly understood markers of disease.|
|Ali Reza Khoshdel; Shane L Carney; Alastair Gillies|
Related Documents :
|18391497 - Clinical features of syndromic craniosynostosis.
20228727 - Renal dysfunction and heart failure.
19057977 - Cerebellar disorders in childhood: cognitive problems.
9211457 - Post polio syndrome: an update for the primary health care provider.
23198177 - Clinical variant of ablepharon macrostomia syndrome.
8286167 - Williams syndrome: a clinical study of children and adults.
|Type: Journal Article|
|Title: Current cardiology reviews Volume: 8 ISSN: 1875-6557 ISO Abbreviation: Curr Cardiol Rev Publication Date: 2012 Feb|
|Created Date: 2012-07-31 Completed Date: - Revised Date: -|
Medline Journal Info:
|Nlm Unique ID: 101261935 Medline TA: Curr Cardiol Rev Country: United Arab Emirates|
|Languages: eng Pagination: 68-76 Citation Subset: IM|
|Department of Epidemiology, Faculty of Medicine, AJA University of medical Sciences, Tehran, Iran. firstname.lastname@example.org.|
|APA/MLA Format Download EndNote Download BibTex|
Journal ID (nlm-ta): Curr Cardiol Rev
Journal ID (iso-abbrev): Curr Cardiol Rev
Journal ID (publisher-id): CCR
Publisher: Bentham Science Publishers
© 2012 Bentham Science Publishers
Received Day: 29 Month: 11 Year: 2011
Revision Received Day: 28 Month: 3 Year: 2012
Accepted Day: 3 Month: 4 Year: 2012
Print publication date: Month: 2 Year: 2012
Electronic publication date: Month: 2 Year: 2012
Volume: 8 Issue: 1
First Page: 68 Last Page: 76
PubMed Id: 22845817
Publisher Id: CCR-8-68
|Circulatory Syndrome: An Evolution of the Metabolic Syndrome Concept!|
|Ali Reza Khoshdelab*|
|Shane L Carneyb|
aDepartment of Epidemiology, Faculty of Medicine, AJA University of medical Sciences, Tehran, Iran
bJohn Hunter Hospital, School of Medicine and Public Health, Faculty of Health, The University of Newcastle, NSW, Australia
|*Address correspondence to this author at the Department of Epidemiology, Faculty of Medicine, AJA University of medical Sciences, Tehran, Iran; P.O. Box 16315-781, Tehran, Iran; Tel:/Fax: +982126317336;
In medical science, a syndrome is defined as an “aggregate of symptoms and signs associated with any morbid process and constituted together they produce the picture of the disease” . These components are usually caused by a unifying underlying pathology and their combination confers a risk that is different from the sum of the parts. The main purpose of such a description is to help in the diagnosis, treatment and prognosis of the disease.
The metabolic syndrome was first described by G.M. Reaven in 1988 to describe a cluster of risk factors contributing to the incidence of diabetes, cardiovascular events and also mortality . The definition of this syndrome remains a matter of debate and has been revised on several occasions by different organizations [3-8]. Despite such diversity, obesity, hyperglycemia, dyslipidemia and hypertension have been constant syndrome components and the central concept of such descriptions is the unity of the background pathophysiologic process and the interaction between the elements.
Several epidemiologic studies have illustrated the relationship between the metabolic syndrome, cardiovascular events and mortality [9-16]; however the syndrome was criticised by the American Diabetes Association a few years ago for its modest consistency and limited clinical application  and the use of the term metabolic syndrome was discouraged. Although the predictive performance of the syndrome for diabetes incidence has been stressed in several studies and meta-analyses , several issues remain unresolved including the presence of potential gender differences in the risk for incident diabetes associated with the metabolic syndrome and whether the metabolic syndrome offers additional prediction beyond its components . Also, its value for both cardiovascular and all-cause mortality is questioned . Hence, it is now important to look back at the issue to ensure about its consistency and usefulness. For instance, the following consideration must be taken for a new definition:
- Insulin resistance has been presumed to be the common pathway for all features of the metabolic syndrome ; yet insulin related measurements are not standardized and vary widely [20, 21]. Despite the general belief, hyperinsulinemia and insulin resistance are not equivalent terms . Besides, while 78% of individuals with metabolic syndrome have insulin resistance, only 48% of patients with insulin resistance have the metabolic syndrome . Therefore the association of hyperinsulinemia and other elements of metabolic syndrome are not constant and many other factors may also play important roles as underlying mechanisms in clustering the risk factors. In other words, insulin resistance may simply be one of many abnormalities linked to a more fundamental, truly unifying pathophysiology .
- Metabolic syndrome diagnosis is not always associated with higher cardiovascular risk, for example an increased risk was not observed in elderly diabetics, non-diabetic American Indians and women with suspected CV disease but normal angiography [17, 23-25]. Additionally, application of different definitions of the syndrome causes 15-20% disagreement in patients classification  and changes the predictive value of the syndrome diagnosis for CV disease and mortality [10, 15, 26]. Therefore the association of the included syndrome components with CV disease and with each other is uncertain. Even reports supporting the metabolic syndrome state that “detecting the metabolic syndrome is only one part of the overall CV risk assessment and is not an adequate tool to estimate 10-year risk for coronary heart disease”. This is possibly because of many other related factors which have not been included as syndrome criteria. In fact, residual analysis of many longitudinal studies demonstrates a high unexplained variance (as much as 47%) when metabolic syndrome components were considered as independent variables .
- Although several epidemiologic studies have demonstrated the relationship between metabolic syndrome and microalbuminuria, this factor was only incorporated into the World Health Organisation criteria for the syndrome. Likewise, renal failure is now recognised as an independent CV risk factor, as is anaemia, but they have not been considered as a part of the metabolic syndrome.
- Despite a large body of evidence of the strong and independent association of endothelioarterial dysfunction with mortality, CV disease, diabetes and renal function[28-40], its impact has been overlooked in metabolic syndrome. Also, cardiac disease has been considered simply as an outcome of metabolic syndrome while it should be an interacting part of the syndrome.
By and large, the current evidence strongly suggests that the metabolic syndrome definition needs significant amendments, which should include the addition of other factors. Furthermore it must be standardized. Therefore, we introduce the term of “circulatory syndrome” instead as a more refined clinical construct since it is composed of many disease markers including cardiac, arterial and renal (respectively abbreviated as MARC) components as well as the traditional risk factors.
Circulatory (MARC) syndrome is a cluster of risk markers with synergic effects. The proposed syndrome consists of eight major components (Fig. 1):
- Abnormal glucose metabolism
- Renal impairment
- Arterial stiffness
- Left ventricular dysfunction
The above markers construct a network of associations while the strength of associations creates manifestation nodes. Then, the syndrome may have several facets of presentation and any given individual may exhibit some dominant features.
The above markers can be simply and non-invasively assessed in outpatient clinical settings, although more complex assessments would be necessary for additional workups.
All of these “markers” are expressed on a background of oxidative stress, inflammation, hypercoagulability and endotheliopathy (underlying factors) and can be accelerated by factors such as aging, obesity, smoking and physical inactivity (predisposing factors).
While mechanisms underlying the circulatory (MARC) syndrome are poorly understood, it must be strongly stated that vascular-endothelial pathways link all and all are of pathological significance. Activation of the renin-angiotensin system, insulin resistance and increased sympathetic activation are all by-products of the underlying pathogenic process (Fig. 2). Since these markers represent the extent of the underlying disease process, they could also manifest as risk factors for other components and thereby enhance their development. The final outcome in this model is the general circulatory health level of the individuals or the ability of the circulatory system to respond to body demands including exercise tolerance and ischemia related symptoms and signs.
Circulatory (MARC) syndrome shares some elements with the metabolic syndrome. However it includes additional metabolic and non-metabolic factors (Table 1).
Diabetes and abnormalities in glucose metabolism are well known risk factors for cardiac, arterial and renal disease as well as anemia [42, 43]. Although insulin resistance and hyperinsulinemia can be attributed to these complications, they may occur with or without insulin resistance because several other mechanisms including advanced glycation end products, autonomic nervous instability, imbalance between the renin-angiotensin system and nitric oxide, hemodynamic changes and endothelial dysfunction with subsequent ADMA accumulation (an inhibitor for nitric oxide synthesis) and adiponectin deficiency also contribute in the process [44-46].
Dyslipidemia including increased LDL and TG as well as low HDL is a major risk in patients with chronic renal disease, hypertension and diabetes[14, 47-49]. Genetic variants of lipoprotein lipase correlate with the presence and degree of albuminuria . Dyslipidemia is an independent determinant of progression toward chronic kidney disease and is a known cardiac risk factor [51, 52]. It also contributes to arterial micro-inflammation and atherosclerosis. From different perspective, the correction of lipid abnormalities can reduce albuminuria in subjects with the metabolic syndrome , decrease inflammatory markers, improve renal function, increase arterial compliance, improve left ventricular function  and prevent CV events. It is noteworthy that obesity was not incorporated into our criteria since there is an opposite relationship between BMI and survival in CKD (reverse epidemiology)  and therefore less obese patients with CKD reach to ESRD.
Hypertension is introduced as the leading risk factor of death according to WHO report of global health .Hypertension and altered blood pressure circadian rhythm are common co-morbidities with diabetes and pre-diabetic states as well as kidney disease. BP is strongly associated with arterial stiffness and promotes left ventricular dysfunction . In the setting of insulin resistance the vasodilatory effect of insulin can be lost but its renal sodium reabsorption stimulation is preserved. In addition, insulin-induced sympathetic activity increases the prevalence of hypertension in the metabolic syndrome . Furthermore, while salt sensitivity is associated with impaired glucose metabolism, oxidative stress, dyslipidemia and insulin resistance [62, 63] ,it also increases efferent glomerular arteriolar tone and thereby raises glomerular capillary pressure and proteinuria . Moreover, salt sensitivity induces blood pressure abnormalities via renal sodium reabsorption and sympathetic overactivity. Therefore, the interlinking of salt-sensitivity and insulin resistance mechanisms with the clinical outcomes raises the possibility of another underlying mechanism joining these together.
Decreased arterial compliance is influenced by both atherosclerosis and arteriosclerosis, as well as functional arterial abnormalities [61, 66]. It occurs very early in the process of kidney disease and DM [67, 68], even preceding microalbuminuria  and has also been observed in normal individuals with a close family history of DM . Recent studies have illustrated that increased central arterial stiffness in hypercholesterolemia, even in newly diagnosed individuals, is associated with low-grade systemic inflammation [70, 71]. Arterial stiffness in turn increases LV load and leads to ventricular stiffness and diastolic dysfunction [72, 73]. It has also been suggested as the linking factor between renal impairment and CV diseases . Of great importance, decreased arterial compliance predicts mortality in variant patient groups, independently from other risk factors [75-78].
Furthermore, albuminuria, arterial stiffness and intima media thickness increase with the increasing number of metabolic syndrome components even before fulfilling the diagnostic criteria for the syndrome, particularly amongst subjects with type 2 DM . In addition, alterations in BP circadian rhythm and BP profile including non-dipper nocturnal BP is now considered as a manifestation of arterial remodelling and is associated with other manifestation of endothelial dysfunction including mA and arterial stiffness.
is now accepted as a marker of renal, cardiac and arterial damage being predictive for the further development of CV events, renal failure and DM [49, 74]. It is also closely associated with the prevalence of anaemia  , hypertension  and metabolic syndrome components . Microalbuminuria commonly occurs early in subjects with abnormal glucose metabolism [67, 81] and is correlated with dyslipidemia , arterial stiffness [83, 84] and increased coagulability  as well as inflammatory markers [86, 87]. Furthermore the presence of microalbuminuria predicts ventricular dysfunction, coronary heart disease and exercise intolerance [88, 89].
Kidney function can not be isolated from the health of the heart and arteries and is also associated with the metabolic syndrome components. Alterations in glomerular structure are seen very early in the obesity-mediated metabolic syndrome . Renal hemodynamic reserve is already impaired in patients with asymptomatic left ventricular dysfunction . In addition, the kidney has an important role in insulin and glucose metabolism and insulin resistance has a predictive value for chronic kidney disease[4, 90]. Renal function has been called the Cinderella of CV risk profile  and the impact of even minor renal dysfunction on CV function is now well established  with endothelial cell dysfunction is likely to be the linking factor between renal and cardiac disease[49, 74, 94]. However endothelial dysfunction in turn is a consequence of inflammation and oxidative stress and is accelerated by these phenomena and is also correlated with a number of the metabolic syndrome components . Decreased arterial compliance increases ventricular wall tension and stiffness and consequently diastolic dysfunction. This in turn may lead to partial renal ischemia, followed by activation of the renin-angiotensin system and tubulointerstitial damage. On the other hand, hyperfiltration which is observed in the early stages of diabetic nephropathy and hypertension [96, 97], leads to increased glomerular pressure and resultant sclerosis which in turn accelerates hypertension.
Anemia is a common finding in DM and has multifactorial mechanisms. Early tubulointerstitial occurs which disease decreases EPO production and moreover inflammatory cytokines reduce EPO responsiveness leading to anaemia. It is also associated with the level of albuminuria .Anaemia in turn, increases the progression toward CKD, oxidative stress, tissue ischemia, ventricular stress and mortality[99-101]. Of interest, a recent study demonstrated the contribution of anemia to the frequent diastolic dysfunction in DM, as well as its association with brain natriuretic peptide (BNP) and suggested using this factor to identify diabetic patients at increased risk of cardiac dysfunction . Therefore, accumulating evidence has introduced anemia as an important risk factor for the circulatory system. On the other hand, correction of anemia improves the prognosis in chronic kidney disease, heart failure and DM and its complications as well as decreasing mortality [101-103]
In contrast to the metabolic syndrome, ventricular function is proposed as an interactive part of the circulatory syndrome. This idea is supported by reports of a lack of a relationship between the metabolic syndrome and mortality in individuals who have good cardiorespiratory fitness . On the other hand even a mild stage of ventricular failure, as manifested by impaired exercise response is predictive for mortality [105, 106]. Ventricular function determines blood pressure and renal perfusion and in turn is influenced by kidney function, anemia and arterial stiffness and microalbuminuria [73, 107]. Diastolic dysfunction occurs early in DM, is correlated with arterial stiffness and affects exercise response . Furthermore, it has been reported that asymptomatic patients with type 2 DM have subclinical ventricular dysfunction which is related to glycated hemoglubin and LDL cholesterol . Also a recent in vitro study demonstrated that myocyte relaxation and Ca2+ handling are abnormal in early uremia, leading to uremic cardiomyopathy .
It is of great interest that some hypoglycaemic agents reduce blood pressure via suppression of the renin-angiotensin system and some ACE inhibitors can reduce insulin resistance in addition to reducing microalbuminuria and arterial stiffness, which raises the possibility of the presence of a common pathway for the adverse effects of hyperglycemia and hypertension[111-113]. Likewise, some lipid lowering agents may exhibit mild anticoagulant and hypotensive effects  and angiotensin inhibitors have anti-inflammatory actions  which also indicate a possible common source of these abnormalities.
It could be expected that genetic predisposition including nephron underdosing, ACE gene polymorphism, congenital tubular defects and also some other factors such as aging, obesity and smoking produce organ damage susceptibility [48, 116-118].
The above evidence suggests that a genetic profile or a common pathologic process induces a network of metabolic (including alterations in glucose, salt, insulin and lipid metabolism) and hemodynamic abnormalities ( due to renin-angiotensin system stimulation, sympathetic overactivity and decreased nitric oxide bioavailability) which are followed by anaemia, hypercoagulability, tissue ischemia, arterial stiffness, hypertension, renal and cardiac dysfunction, the other features of the circulatory syndrome (Fig. 2).
It seems that inflammation is the fuel that “burns” the circulatory syndrome. The association between inflammatory markers and both diabetes and hypertension is so strong that these diseases has recently been redefined as inflammatory diseases, as has atheroma[119-122]. Likewise, insulin resistance has a strong link with inflammation, although additional mechanisms such as genetic factors may interfere in this relationship. Additionally, inflammation is known to be a modifier of the relationship between microalbuminuria and hypertension [86, 124]. Hence, CRP has been frequently promoted as a part of the metabolic syndrome [11, 27, 125].
Advanced glycation end products (AGEs) which accumulate in diabetes activate inflammatory cells. Moreover, inflammatory markers such as CRP are now considered to be independent predictors of diabetes  and its complications including left ventricular hypertrophy, endothelial dysfunction, albuminuria and renal failure [74, 95, 126, 127].
There is a close relationship between inflammation and hypercoagulability [87, 130]. Furthermore, hypercoagulability is also linked to the metabolic syndrome, dyslipidemia, anaemia and even the hemodynamic response to exercise [129, 131-133]. It is associated with a poorer outcome in coronary artery disease, heart failure and is correlated with the severity of target-organ damage including renal impairment [134-136]. Moreover, diabetic and metabolic syndrome patients are at high risk for thrombotic events [137-139] and have an increased level of clotting factors including tissue plasminogen activator (tPA) and von Willenbrand Factor (vWF) and D-dimer when compared to the controls . Additionally insulin and lipids may have direct effects on inhibition of coagulation and platelet function through the nitric oxide pathway, which is impaired in patients with diabetes .
By and large, this interlinking mesh of inflammatory mediators, oxidative stress, endotheliopathy and hypercoagulability makes a common soil for development of the circulatory syndrome.
The above description of the “circulatory (MARC) syndrome” clearly has clinical applications. Identification of commonly evaluated markers such as blood pressure, glucose and lipids in a patient should prompt a search for other circulatory syndrome markers. Suspicion about the presence of the circulatory syndrome should facilitate decision making for diagnostic procedures in asymptomatic but high risk patients. Also treatment of each syndrome component should be accompanied by management of the other components. Furthermore, any difficulty in treating one circulatory syndrome marker should probably leads to a more aggressive treatment program for other components as is currently proposed in patients with renal disease, diabetes and associated hypertension. Hence, management of circulatory syndrome would need an interdisciplinary approach with the collaboration of different medical subspecialties.
Although circulatory syndrome is theoretically logical, and is supported by evidence from separate studies for each component, integrated epidemiologic studies are required to examine its consistency, validity and predictive value for adverse outcomes such as disability and mortality. Also it is important to investigate whether other markers can be added to the cluster and improve its performance.
Circulatory (MARC) syndrome is a cluster of interactive risk markers, combining renal, arterial, cardiac and metabolic elements into a coherent whole. These components develop on a background of inflammation, oxidative stress, hypercoagulability and endotheliopathy and while accelerated by one another, other factors including aging, obesity, physical inactivity and smoking contribute to the syndrome pathology. It’s consistency, diagnostic criteria and clinical utility still need to be investigated.
|1.||Stedman's Medical DictionaryYear: 200027th edition edBaltimoreLippincott, Williams and Wilkins1746|
|2.||Reaven GM. Role of insulin resistance in human diseaseDiabetesYear: 1988371215956073056758|
|3.||Ormezzano O,JP Baguet,P Francois,et al. Is there any real target organ damage associated with white-coat normotension?Clin Auton ResYear: 2004143160615241644|
|4.||Balkau B,MA Charles. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR)Diabet MedYear: 1999165442310342346|
|5.||Einhorn D,GM Reaven,RH Cobin,et al. American College of Endocrinology position statement on the insulin resistance syndromeEndocr PractYear: 2003932375212924350|
|6.||Grundy SM,HB Brewer Jr,Cleeman JI,et al. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definitionCirculationYear: 20041093433814744958|
|7.||Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)JamaYear: 20012851924869711368702|
|8.||Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final reportCirculationYear: 200210625314342112485966|
|9.||Alexander CM,PB Landsman,SM Teutsch,et al. NCEP-defined metabolic syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 50 years and olderDiabetesYear: 20035251210412716754|
|10.||Athyros VG,ES Ganotakis,MS Elisaf,et al. Prevalence of vascular disease in metabolic syndrome using three proposed definitionsInt J CardiolYear: 2006|
|11.||Kahn R,J Buse,E Ferrannini,et al. The metabolic syndrome: time for a critical appraisal: joint statement from the American Diabetes Association and the European Association for the Study of DiabetesDiabetes CareYear: 2005289228930416123508|
|12.||Malik S,ND Wong,SS Franklin,et al. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adultsCirculationYear: 20041101012455015326067|
|13.||Girman CJ,T Rhodes,M Mercuri,et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)Am J CardiolYear: 20049321364114715336|
|14.||Ford ES. The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality StudyAtherosclerosisYear: 200417323091415064107|
|15.||Hunt KJ,RG Resendez,K Williams,et al. National Cholesterol Education Program versus World Health Organization metabolic syndrome in relation to all-cause and cardiovascular mortality in the San Antonio Heart StudyCirculationYear: 2004110101251715326061|
|16.||Scuteri A,SS Najjar,CH Morrell,et al. The metabolic syndrome in older individuals: prevalence and prediction of cardiovascular events: the Cardiovascular Health StudyDiabetes CareYear: 2005284882715793190|
|17.||Cameron A. The metabolic syndrome: Validity and utility of clinical definitions for cardiovascular disease and diabetes risk predictionMaturitasYear: 2010651172120031349|
|18.||Ford ES,MB Schulze,T Pischon,et al. Metabolic syndrome and risk of incident diabetes: findings from the European Prospective Investigation into Cancer and Nutrition-Potsdam StudyCardiovascular DiabetologyYear: 2008735|
|19.||Reaven G. The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goalsEndocrinol Metab Clin North AmYear: 200433228330315158520|
|20.||Robbins DC,L Andersen,R Bowsher,et al. Report of the American Diabetes Association's Task Force on standardization of the insulin assayDiabetesYear: 1996452242568549870|
|21.||Wallace TM,JC Levy,DR Matthews. Use and abuse of HOMA modelingDiabetes CareYear: 200427614879515161807|
|22.||Liao Y,S Kwon,S Shaughnessy,et al. Critical evaluation of adult treatment panel III criteria in identifying insulin resistance with dyslipidemiaDiabetes CareYear: 20042749788315047659|
|23.||Bruno G,F Merletti,A Biggeri,et al. Metabolic syndrome as a predictor of all-cause and cardiovascular mortality in type 2 diabetes: the Casale Monferrato StudyDiabetes CareYear: 2004271126899415505006|
|24.||Resnick HE,K Jones,G Ruotolo,et al. Insulin resistance, the metabolic syndrome, and risk of incident cardiovascular disease in nondiabetic american indians: the Strong Heart StudyDiabetes CareYear: 2003263861712610050|
|25.||Marroquin OC,KE Kip,DE Kelley,et al. Metabolic syndrome modifies the cardiovascular risk associated with angiographic coronary artery disease in women: a report from the Women's Ischemia Syndrome EvaluationCirculationYear: 200410967142114970105|
|26.||Lakka HM,DE Laaksonen,TA Lakka,et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged menJamaYear: 20022882127091612460094|
|27.||Grundy SM,JI Cleeman,SR Daniels,et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific StatementCirculationYear: 20051121727355216157765|
|28.||Amar J,JB Ruidavets,B Chamontin,et al. Arterial stiffness and cardiovascular risk factors in a population-based studyJ HypertensYear: 2001193381711288807|
|29.||Asmar R,A Rudnichi,J Blacher,et al. Pulse pressure and aortic pulse wave are markers of cardiovascular risk in hypertensive populationAm J HypertensionYear: 200114917|
|30.||Blacher J,ME Safar,AP Guerin,et al. Aortic pulse wave velocity index and mortality in end-stage renal diseaseKidney internationalYear: 20036318526012675863|
|31.||Boutouyrie P,Tropeano AI,R Asmar,et al. Aortic stiffness is an independent predictor of primary coronary events in hypertensive patientsHypertensionYear: 200239101511799071|
|32.||London GM,JN Cohn. Prognostic application of arterial stiffness: task forcesAm J HypertensYear: 2002158754812160201|
|33.||Laurent S,J Cockcroft,L Van Bortel,et al. Expert consensus document on arterial stiffness: methodological issues and clinical applicationsEur Heart JYear: 20062721258860517000623|
|34.||Mourad A,A Khoshdel,S Carney,et al. Haemodialysis-unresponsive blood pressure: cardiovascular mortality predictor?Nephrology (Carlton)Year: 20051054384116221091|
|35.||Khoshdel AR,SL Carney,P Trevillian,et al. Evaluation of arterial stiffness and pulse wave reflection for cardiovascular risk assessment in diabetic and nondiabetic kidney transplant recipientsIran J Kidney DisYear: 2010432374320622314|
|36.||Khoshdel AR,SL Carney. HEMODYNAMIC RESPONSE TO EXERCISE PREDICTS THE DEVELOPMENT OF SEVERE RENAL FAILUREAmerican Heart AssociationYear: 2008in 14th World Congress on Heart DiseaseJuly 2008Toronto, CANADA|
|37.||Khoshdel AR,SL Carney,S White. Disturbed hemodynamic cardiac exercise stress test response in non-smoking, normolipidemic, normotensive, diabetic subjectsDiabetes Res Clin PractYear: 2007752193916860431|
|38.||Khoshdel AR,SL Carney,BR Nair,et al. Better management of cardiovascular diseases by pulse wave velocity: combining clinical practice with clinical research using evidence-based medicineClin Med ResYear: 200751455217456834|
|39.||Khoshdel AR,A Thakkinstian,SL Carney,et al. Estimation of an age-specific reference interval for pulse wave velocity: a meta-analysisJ HypertensYear: 20062471231716794467|
|40.||Khoshdel AR,SL Carney,A Gillies,et al. The impact of diabetes mellitus on arterial stiffness in end-stage renal disease (Abstract)NephrologyYear: 200510SupplementA21|
|41.||Khoshdel AR. Metabolic syndrome: Erasing the problem or constructing a better answerBMJ rapid response at www.bmj.comYear: 2008Month: 3 Day: 27th|
|42.||Knudsen ST,PL Poulsen,KW Hansen,et al. Pulse pressure and diurnal blood pressure variation: association with micro- and macrovascular complications in type 2 diabetesAm J HypertensYear: 20021532445011939615|
|43.||Thomas MC,RJ MacIsaac,C Tsalamandris,et al. Anemia in patients with type 1 diabetesJ Clin Endocrinol MetabYear: 200489943596315356033|
|44.||Eckel RH,SM Grundy,PZ Zimmet. The metabolic syndromeLancetYear: 2005365946814152815836891|
|45.||Bongartz LG,MJ Cramer,PA Doevendans,et al. The severe cardiorenal syndrome: 'Guyton revisited'Eur Heart JYear: 200526111715615794|
|46.||Becker B,F Kronenberg,JT Kielstein,et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease studyJ Am Soc NephrolYear: 20051641091815743998|
|47.||Saydah SH,J Fradkin,CC Cowie. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetesJamaYear: 200429133354214734596|
|48.||Fox CS,MG Larson,EP Leip,et al. Predictors of new-onset kidney disease in a community-based populationJamaYear: 200429178445014970063|
|49.||Amann K,C Wanner,E Ritz. Cross-Talk between the Kidney and the Cardiovascular SystemJ Am Soc NephrolYear: 20061782112916825329|
|50.||Mattu RK,J Trevelyan,EW Needham,et al. Lipoprotein lipase gene variants relate to presence and degree of microalbuminuria in Type II diabetesDiabetologiaYear: 20024569051312107736|
|51.||Zoccali C. Cardiorenal risk as a new frontier of nephrology: research needs and areas for interventionNephrol Dial TransplantYear: 200217 Suppl 1150412386260|
|52.||Locatelli F,J Bommer,GM London,et al. Cardiovascular disease determinants in chronic renal failure: clinical approach and treatmentNephrol Dial TransplantYear: 20011634596811239016|
|53.||Colhoun HM,DJ Betteridge,PN Durrington,et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trialLancetYear: 200436494356859615325833|
|54.||Geluk CA,FW Asselbergs,HL Hillege,et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention TrialEur Heart JYear: 2005261313142015820998|
|55.||Sola S,MQ Mir,S Lerakis,et al. Atorvastatin improves left ventricular systolic function and serum markers of inflammation in nonischemic heart failureJ Am Coll CardiolYear: 2006472332716412856|
|56.||Elisaf M,DP Mikhailidis. Statins and renal functionAngiologyYear: 200253549350212365855|
|57.||Dogra GK,GF Watts,DC Chan,et al. Statin therapy improves brachial artery vasodilator function in patients with Type 1 diabetes and microalbuminuriaDiabet MedYear: 20052232394215717868|
|58.||Bakker SJ,RT Gansevoort,D de Zeeuw. Metabolic syndrome: a fata morgana?Nephrol Dial TransplantYear: 2007221152017050636|
|59.||Global Health Risks: Morbidity and burden of disease attributable to selected major risksWHO Global ReportsYear: 200970|
|60.||Zandi-Nejad K,VA Luyckx,BM Brenner. Adult hypertension and kidney disease: the role of fetal programmingHypertensionYear: 2006473502816415374|
|61.||Vlachopoulos C,M O'Rourke. Genesis of the normal and abnormal arterial pulseCurr Probl CardiolYear: 20002553036710822214|
|62.||Fuenmayor N,E Moreira,LX Cubeddu. Salt sensitivity is associated with insulin resistance in essential hypertensionAm J HypertensYear: 1998114 Pt 13974029607376|
|63.||Sharma AM,U Schorr,A Distler. Insulin resistance in young salt-sensitive normotensive subjectsHypertensionYear: 199321327398478036|
|64.||Weir MR. Impact of salt intake on blood pressure and proteinuria in diabetes: importance of the renin-angiotensin systemMiner Electrolyte MetabYear: 1998246438459930383|
|65.||Resnick LM. Ionic basis of hypertension, insulin resistance, vascular disease, and related disorders. The mechanism of "syndrome X"Am J HypertensYear: 199364123S134S8507440|
|66.||Cohn JN,AA Quyyumi,NK Hollenberg,et al. Surrogate markers for cardiovascular disease: functional markersCirculationYear: 200410925 Suppl 1IV314615226249|
|67.||Kimoto E,T Shoji,K Shinohara,et al. Preferential stiffening of central over peripheral arteries in type 2 diabetesDiabetesYear: 20035224485212540620|
|68.||Hopkins KD,ED Lehmann,RL Jones,et al. A family history of NIDDM is associated with decreased aortic distensibility in normal healthy young adult subjectsDiabetes CareYear: 199619550138732717|
|69.||Ratto E,G Leoncini,F Viazzi,et al. Ambulatory arterial stiffness index and renal abnormalities in primary hypertensionJ HypertensYear: 200624102033816957564|
|70.||Pirro M,G Schillaci,G Savarese,et al. Low-grade systemic inflammation impairs arterial stiffness in newly diagnosed hypercholesterolaemiaEur J Clin InvestYear: 20043453354115147330|
|71.||Wilkinson I,and JR Cockcroft. Cholesterol, lipids and arterial stiffnessAdv CardiolYear: 2007442617717075215|
|72.||Mottram PM,BA Haluska,R Leano,et al. Relation of arterial stiffness to diastolic dysfunction in hypertensive heart diseaseHeartYear: 200591121551616287739|
|73.||Gates PE,H Tanaka,J Graves,et al. Left ventricular structure and diastolic function with human ageing. Relation to habitual exercise and arterial stiffnessEur Heart JYear: 2003242422132014659773|
|74.||Ritz E. Heart and kidney: fatal twins?Am J MedYear: 20061195 Suppl 1S31916563946|
|75.||Cruickshank K,L Riste,SG Anderson,et al. Aortic Pulse-Wave Velocity and its relationship to Mortality in Diabetes and Glucose intoleranceCirculationYear: 200210620859012379578|
|76.||Laurent S,P Boutouyrie,R Asmar,et al. Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patientsHypertensionYear: 20013712364111358934|
|77.||London GM,J Blacher,B Pannier,et al. Arterial wave reflections and survival in end-stage renal failureHypertensionYear: 2001383434811566918|
|78.||Meaume S,A Rudnichi,A Lynch,et al. Aortic pulse wave velocity as a marker of cardiovascular disease in subjects over 70 years oldJ HypertensYear: 2001195871711393669|
|79.||Yokoyama H,M Kuramitsu,S Kanno,et al. Relationship between metabolic syndrome components and vascular properties in Japanese type 2 diabetic patients without cardiovascular disease or nephropathyDiabetes Res Clin PractYear: 2006|
|80.||Cerasola G,S Cottone,G Mule,et al. Microalbuminuria, renal dysfunction and cardiovascular complication in essential hypertensionJ HypertensYear: 1996147915208818932|
|81.||Cruickshank K,L Riste,SG Anderson,et al. Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function?CirculationYear: 20021061620859012379578|
|82.||Niskanen L,M Uusitupa,H Sarlund,et al. Microalbuminuria predicts the development of serum lipoprotein abnormalities favouring atherogenesis in newly diagnosed type 2 (non-insulin-dependent) diabetic patientsDiabetologiaYear: 1990334237432347436|
|83.||Smith A,J Karalliedde,L De Angelis,et al. Aortic pulse wave velocity and albuminuria in patients with type 2 diabetesJ Am Soc NephrolYear: 200516410697515743996|
|84.||Kohara K,Y Tabara,R Tachibana,et al. Microalbuminuria and arterial stiffness in a general population: the Shimanami Health Promoting Program (J-SHIPP) studyHypertens ResYear: 2004277471715302983|
|85.||Peppa-Patrikiou M,M Dracopoulou,and C Dacou-Voutetakis. Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factorsMetabolismYear: 199847111408129826222|
|86.||Pedrinelli R,G Dell'Omo,V Di Bello,et al. Low-grade inflammation and microalbuminuria in hypertensionArterioscler Thromb Vasc BiolYear: 200424122414915486313|
|87.||Aso Y,N Yoshida,K Okumura,et al. Coagulation and inflammation in overt diabetic nephropathy: association with hyperhomocysteinemiaClin Chim ActaYear: 20043481-21394515369747|
|88.||Kelbaek H,T Jensen,B Feldt-Rasmussen,et al. Impaired left-ventricular function in insulin-dependent diabetic patients with increased urinary albumin excretionScand J Clin Lab InvestYear: 1991515467731947732|
|89.||Estacio RO,JG Regensteiner,EE Wolfel,et al. The association between diabetic complications and exercise capacity in NIDDM patientsDiabetes CareYear: 199821229159539998|
|90.||Peralta CA,M Kurella,JC Lo,et al. The metabolic syndrome and chronic kidney diseaseCurr Opin Nephrol HypertensYear: 2006154361516775449|
|91.||Magri P,MA Rao,S Cangianiello,et al. Early impairment of renal hemodynamic reserve in patients with asymptomatic heart failure is restored by angiotensin II antagonismCirculationYear: 199898252849549860786|
|92.||Sarafidis PA,LM Ruilope. Insulin resistance, hyperinsulinemia, and renal injury: mechanisms and implicationsAm J NephrolYear: 20062632324416733348|
|93.||Ruilope LM,DJ van Veldhuisen,E Ritz,et al. Renal function: the Cinderella of cardiovascular risk profileJ Am Coll CardiolYear: 20013871782711738274|
|94.||Safar ME,GM London,GE Plante. Arterial stiffness and kidney functionHypertensionYear: 2004432163814732732|
|95.||Zoccali C,R Maio,G Tripepi,et al. Inflammation as a mediator of the link between mild to moderate renal insufficiency and endothelial dysfunction in essential hypertensionJ Am Soc NephrolYear: 2006174 Suppl 2S64816565250|
|96.||Levine DZ. Hyperfiltration, nitric oxide, and diabetic nephropathyCurr Hypertens RepYear: 200682153716672149|
|97.||Palatini P,P Mormino,F Dorigatti,et al. Glomerular hyperfiltration predicts the development of microalbuminuria in stage 1 hypertension: the HARVESTKidney IntYear: 20067035788416788693|
|98.||Weiss G,LT Goodnough. Anemia of chronic diseaseN Engl J MedYear: 20053521010112315758012|
|99.||Srivastava PM,MC Thomas,P Calafiore,et al. Diastolic dysfunction is associated with anaemia in patients with Type II diabetesClin Sci (Lond)Year: 200611011091616181149|
|100.||Smith KJ,AJ Bleyer,WC Little,et al. The cardiovascular effects of erythropoietinCardiovasc ResYear: 20035935384814499855|
|101.||Ritz E. Managing anaemia and diabetes: a future challenge for nephrologistsNephrol Dial TransplantYear: 200520 Suppl 6vi21515958822|
|102.||Kovesdy CP,BK Trivedi,K Kalantar-Zadeh,et al. Association of anemia with outcomes in men with moderate and severe chronic kidney diseaseKidney IntYear: 2006693560416395253|
|103.||Streeter RP,Mancini D. Treatment of anemia in the patient with heart failureCurr Treat Options Cardiovasc MedYear: 2005743273216004863|
|104.||Katzmarzyk PT,TS Church,SN Blair. Cardiorespiratory fitness attenuates the effects of the metabolic syndrome on all-cause and cardiovascular disease mortality in menArch Intern MedYear: 2004164101092715159266|
|105.||Jouven X,JP Empana,PJ Schwartz,et al. Heart-rate profile during exercise as a predictor of sudden deathN Engl J MedYear: 2005352191951815888695|
|106.||Williams SG,M Jackson,LL Ng,et al. Exercise duration and peak systolic blood pressure are predictive of mortality in ambulatory patients with mild-moderate chronic heart failureCardiologyYear: 20051044221616158008|
|107.||Bonapace S,A Rossi,M Cicoira,et al. Aortic distensibility independently affects exercise tolerance in patients with dilated cardiomyopathyCirculationYear: 2003107121603812668493|
|108.||Boyer JK,S Thanigaraj,KB Schechtman,et al. Prevalence of ventricular diastolic dysfunction in asymptomatic, normotensive patients with diabetes mellitusAm J CardiolYear: 2004937870515050491|
|109.||Vinereanu D,E Nicolaides,AC Tweddel,et al. Subclinical left ventricular dysfunction in asymptomatic patients with Type II diabetes mellitus, related to serum lipids and glycated haemoglobinClin Sci (Lond)Year: 20031055591912831396|
|110.||McMahon AC,RU Naqvi,MJ Hurst,et al. Diastolic dysfunction and abnormality of the Na+/Ca2+ exchanger in single uremic cardiac myocytesKidney IntYear: 20066958465116518344|
|111.||Ando K,T Fujita. Anti-diabetic effect of blockade of the renin-angiotensin systemDiabetes Obes MetabYear: 20068439640316776746|
|112.||Derosa G,AF Cicero,A Dangelo,et al. Thiazolidinedione effects on blood pressure in diabetic patients with metabolic syndrome treated with glimepirideHypertens ResYear: 200528119172416555581|
|113.||Raji A,J Plutzky. Insulin resistance, diabetes, and atherosclerosis: thiazolidinediones as therapeutic interventionsCurr Cardiol RepYear: 2002465142112379175|
|114.||Undas A,KE Brummel-Ziedins,KG Mann. Statins and blood coagulationArterioscler Thromb Vasc BiolYear: 20052522879415569822|
|115.||Fliser D,K Buchholz,H Haller. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammationCirculationYear: 200411091103715313950|
|116.||Gross ML,K Amann,E Ritz. Nephron number and renal risk in hypertension and diabetesJ Am Soc NephrolYear: 200516 Suppl 1S27915938029|
|117.||Hobson A,PA Kalra,PR Kalra. Cardiology and nephrology: time for a more integrated approach to patient care?Eur Heart JYear: 200526161576815975992|
|118.||Lee YJ,JC Tsai. ACE gene insertion/deletion polymorphism associated with 1998 World Health Organization definition of metabolic syndrome in Chinese type 2 diabetic patientsDiabetes CareYear: 20022561002812032106|
|119.||Zozulinska D,B Wierusz-Wysocka. Type 2 diabetes mellitus as inflammatory diseaseDiabetes Res Clin PractYear: 2006|
|120.||Li JJ,CH Fang,RT Hui. Is hypertension an inflammatory disease?Med HypothesesYear: 20056422364015607546|
|121.||Li JJ,JL Chen. Inflammation may be a bridge connecting hypertension and atherosclerosisMed HypothesesYear: 2005645925915780486|
|122.||Lind L. Circulating markers of inflammation and atherosclerosisAtherosclerosisYear: 2003169220321412921971|
|123.||Shoelson SE,J Lee,AB Goldfine. Inflammation and insulin resistanceJ Clin InvestYear: 20061167179380116823477|
|124.||Stuveling EM,SJ Bakker,H Hillege,et al. C-reactive protein modifies the relationship between blood pressure and microalbuminuriaHypertensionYear: 2004434791614967837|
|125.||Ridker PM,PW Wilson,SM Grundy. Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?CirculationYear: 20041092328182515197153|
|126.||Stehouwer CD,MA Gall,JW Twisk,et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of deathDiabetesYear: 200251411576511916939|
|127.||Palmieri V,RP Tracy,MJ Roman,et al. Relation of left ventricular hypertrophy to inflammation and albuminuria in adults with type 2 diabetes: the strong heart studyDiabetes CareYear: 200326102764914514577|
|128.||Ridker PM,N Rifai,NR Cook,et al. Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in womenJamaYear: 200529433263316030277|
|129.||Sagastagoitia JD,Y Saez,M Vacas,et al. Association between inflammation, lipid and hemostatic factors in patients with stable anginaThromb ResYear: 2006|
|130.||Devaraj S,RS Rosenson,I Jialal. Metabolic syndrome: an appraisal of the pro-inflammatory and procoagulant statusEndocrinol Metab Clin North AmYear: 200433243153 table of contents. 15158528|
|131.||Matteucci E,J Rosada,M Pinelli,et al. Systolic blood pressure response to exercise in type 1 diabetes families compared with healthy control individualsJ HypertensYear: 200624917455116915023|
|132.||Keung YK,and J Owen. Iron deficiency and thrombosis: literature reviewClin Appl Thromb HemostYear: 20041043879115497026|
|133.||Nieuwdorp M,ES Stroes,JC Meijers,et al. Hypercoagulability in the metabolic syndromeCurr Opin PharmacolYear: 200552155915780824|
|134.||Sechi LA,L Zingaro,C Catena,et al. Relationship of fibrinogen levels and hemostatic abnormalities with organ damage in hypertensionHypertensionYear: 20003669788511116111|
|135.||Danesh J,S Lewington,SG Thompson,et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysisJamaYear: 200529414179980916219884|
|136.||Marcucci R,AM Gori,F Giannotti,et al. Markers of hypercoagulability and inflammation predict mortality in patients with heart failureJ Thromb HaemostYear: 20064510172216689753|
|137.||Vicari AM,MV Taglietti,F Pellegatta,et al. Deranged platelet calcium homeostasis in diabetic patients with end-stage renal failure. A possible link to increased cardiovascular mortality?Diabetes CareYear: 19961910106268886550|
|138.||Haffner SM,L Mykkanen,A Festa,et al. Insulin-resistant prediabetic subjects have more atherogenic risk factors than insulin-sensitive prediabetic subjects: implications for preventing coronary heart disease during the prediabetic stateCirculationYear: 200010199758010704163|
|139.||Isomaa B,P Almgren,T Tuomi,et al. Cardiovascular morbidity and mortality associated with the metabolic syndromeDiabetes CareYear: 2001244683911315831|
|140.||Bloomgarden ZT. Third Annual World Congress on the Insulin Resistance Syndrome: Atherothrombotic diseaseDiabetes CareYear: 200629819738016873814|
|141.||Juhan-Vague I,MC Alessi,A Mavri,et al. Plasminogen activator inhibitor-1, inflammation, obesity, insulin resistance and vascular riskJ Thromb HaemostYear: 2003171575912871293|
Keywords: Keywords Circulatory system, metabolic syndrome, renal function, ventricular function, arterial stiffness, anaemia..
Previous Document: Acute cardioembolic cerebral infarction: answers to clinical questions.
Next Document: Beta Blocker Use After Acute Myocardial Infarction in the Patient with Normal Systolic Function: Whe...